triumph 1 retatrutide produces up to 30.3% weight loss in Phase 3 trial 30% Weight Loss?! Retatrutide CRUSHES

Tamoxifen was included in the standard of care for long-term adjuvant therapy for estrogen receptor-positive breast cancer (Krishnamurthy et al., 2022)

Unlike many other peptides, DSIP has no single, clearly defined receptor

5H, LPS-treated BV2 cells without any formulation treatment displayed minimal intracellular green signal from FITC-labeled A 142 , with green fluorescence primarily localized around the cell membranes

For example, degradation of PYY (136) to the more potent gastric inhibitor PYY (336) is prevented by DPP-4 inhibition.50 Clinical implications Glucose control A complex interaction exists between glycaemia and gastric motility.51 Higher glucose levels delay, whereas lower levels stimulate gastric emptying.5254 As a result, the inhibitory effect of GLP-1 on gastric emptying is more pronounced during hyperglycaemia and reduced during hypoglycaemia.52 ,53 Conversely, gastric emptying rate is accountable for approximately 35% of the postprandial glucose excursions.55 ,56 Consequently, inhibition of gastric emptying by GLP-1 and short-acting GLP-1RAs reduces postprandial glucose levels.34 ,57 The significance of this effect was demonstrated in a study where co-infusion of the prokinetic erythromycin blunted the inhibiting effect of GLP-1 infusion on postprandial glucose excursions.58 Weight loss While DPP-4Is are weight-neutral, GLP-1RAs (short-acting and long-acting) induce weight loss in a dose-dependent manner.59 Recently, a high-dose preparation of the long-acting GLP-1RA liraglutide (3.0 mg) has been approved for weight reduction.60 Mechanisms underlying this weight loss are still incompletely understood

Congratulations to you and your beautiful boy, and have a wonderful year